An open trial of risperidone in the treatment of schizophrenia in the University of Malaya Medical Centre by Jambunathan, S.T. & Aili, H.H.
ORIGINAL PAPER
An Open Trial of Risperidone in the Treatment
of Schizophrenia In the University of Malaya
Medical Centre
Stephen T. Jambunathan, Aili Hanim Hashim
Objective: To apalyze the pattern of use and outcome of patients with Schizophrenia
treated with Risperidone over a minimum period of one year In an open label
longitudinal descriptive study.
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Methods: The first 94 patients aged 14 — 72 years
with schizophrenia were recruited from the University
of Malaya Medical Centre. Patients were treated
with risperidone and assessed at baseline (week 0),
week 1, week 4, week 24, and week 52. Data was
collected using the Risperidone Study Questionnaire.
The response was assessed using the Clinical Global
Impression (CGI) and Global Evaluation (GE) scales
and the rate ofreduction ofnumberofhospitalization
comparing the year before and after the onset of
treatment. The outcome was assessed by evaluation
-of factors leading to discontinuation of treatment.
Safety was assessed by investigating the side effects
that led to discontinuation of treatment and the
eventual outcome of all patients.
Results: 62 patients with a mean age of 33.7 ± 12.0
yrs (range 14 to 72) were analyzed. The sex
distribution was 29 male patients (46.8%) and 33
femalepatients(53.2%) with racial distributionbeing
34 Chinese (54.8%),16Malay(25.8%)and 12Indian
patients (19.4%). Out of 94 patients put on
risperidone, 62(66.0%) were still on medication after
one year. The initial clinical status of the recruited
patients were treatment refractory (42%), chronic
controlled (12%), acute exacerbation (21%), BPS
prone (15%), 1° episode (2%), elective switch-over
(8%) and with combination of reasons (15%). Over
aperiod ofone year, there was a discontinuation rate
of34.0%. Mean CGI score reduced from 4.9 f 1.0 at
week 0 (baseline) to 2.5 f 0.8 at week 52 (endpoint),
p < 0.001. Mean Global Evaluation by Investigator
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(GEI) score improved from 5.7 f 0.9 at week 4
(baseline) to 6.5 * 0.9 at week 52 (endpoint), p
0.001. Mean Global Evaluation by Patient (GEP)
score improved from 5.7 ± 0.9 at week 4 (baseline)
to 6.5 t 1.0 at week 52 (endpoint), P c
 0.001. There
was a 76.9% reduction in the number of admissions
one year post-treatment (endpoint) as compared to
baseline of the study, p < 0.001.
Conclusions: Overall, the therapy of schizophrenia
with risperidone was significantly effective and safe.
However in order to maximize patient benefit doctors
should take into consideration various influencing
factors that may lead to early discontinuation of the
medication.
Introduction
The advent ofantipsychotics began with the discovery
of reserpine, a constituent of the Rawolfia shrub
which was found to be effective in the treatment of
psychosis. In 1952, chlorpromazine was discovered
as an effective antipsychotic and this was followed by
the introduction of many other antipsychotic drugs.
The use of these drugs began to revolutionize the
treatment of psychosis with 50% - 75% of the
patients showing significant clinical response.
However, the early antipsychotics also have many
major limitations such as extrapyramidal side effects,
neuroleptic malignant syndrome and tardive
dyskinesia. In addition, these drugs are not effective
in the treatment of the negative symptoms of
schizophrenia. There is also a h igh percentage ofnon-
responders which is a major public health concern
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because of the debilitating effects of the illness.
The high incidence ofextrapyramidal symptoms
(EPS) with the conventional antipsychotics often•
lead to poor compliance and thus an increased risk of
relapse. Approximately 20% - 30% of patients
develop tardive dyskinesia (TD) and about 0.5% -
1.5% suffer from neuroleptic malignant syndrome
(1). The need for safer and better drugs led to the
discovery of atypical or novel antipsychotics such
as clozapine, risperidone, olanzapine, sertindole,
zotepine, quetiapine and ziprasidone (2,3). With the
discovery of numerous atypical antipsychotics, the
clinical implications have increased tremendously.
We now have more effective medications for the
treatment refractory schizophrenia and for the
treatment of negative symptoms. Compliance has
increased due to better response, improved insight,
find better side effect profile. Patients on atypical
antipsychotics have a much lesser risk of developing
tardive dyskinesia (TD). In addition, in many cases,
a reduction in TD has been reported (4,5,6). With a
lower incidence ofEPS, the need for anticholinergics
has been greatly reduced. These antipsychotics are
therefore more appropriate for patients with organic
brain syndromes, who are more susceptible to the
side effects ofanticholinergics. Anticholinergics have
also been implicated as the cause of significant
cognitive deficits in patients with schizophrenia (7).
Apart from a decreased need for anticholinergics,
atypical antipsychotics also play a role in the
amelioration of neurocognitive deficits in
schizophrenia (8).
Studies with ritanserin, a specific 5HT 2 receptor
antagonist in the early 1980's demonstrated the role
of5HT2 receptorantagonism in ameliorating negative
symptoms and decreasing the incidence ofEPS. With
further research, the Serotonin-Dopamine Antagonist
(SDA) group of antipsychotics was discovered. In
1984, risperidone was chosen for further testing and
was first used in the USA in 1994. This drug was
introduced in Malaysia in January 1997. Risperidone
belongs to anew group of drugs called benzisoxazole
derivatives. It acts through D2 receptor antagonism
in the mesolimbic pathway leading to the reduction
of positive symptoms. 5HT2 receptor antagonism
leads to the reduction of negative and affective
symptoms, as well as increases dopamine in the
nigrostriatal region thus resulting in a reduction of
EPS (9). With the serotonin-dopamine antagonism
mechanism of action, risperidone is said to be more
effective than older antipsychotics. It is also more
tolerable due to theadd iti onal advantage of having no
affinity to the cholinergic muscarinic receptors.
Objectives of the study
The aim of the study is to assess the following:
1. The various indications of use of Risperidone.
2. The efficacy in terms of doctor and patient
satisfaction.
3. The outcome in terms of side effects, dosages
and reduction in the rate of re-hospitalization.
4. Methods.ofmore effective switching over from
one antipsychotic to another.
5. The varying prescribing philosophies and their
shortcomings in order to improve on the
methods of use of atypical antipsychotics.
Methods
This was a descriptive, 52-week, open label flexible
dose study designed to evaluate the efficacy and
safety of risperidone in the treatment of patients
with schizophrenia in the University of Malaya
Medical Centre.
Patients
Male and Female adult inpatients and outpatients
diagnosed according to DSM IV criteria for
schizophrenia disorder were recruited. As this was
an open labeled trial of a then new drug, the first
hundred patients put on Risperidone were included.
Assessment Parameters
The primary efficacy parameters wereClinical Global
Impression (CGI) and Global Evaluation (GE) by the
investigators and patients.
Secondary efficacy parameters were evaluation
of factors leading to discontinuation of treatment and
effectiveness ofrisperidone in terms ofreduction in
the number of hospitalizations.
The safety and tolerability of risperidone was
assessed by monitoring the side effects that led to
discontinuation.
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Treatment and Assessment Schedule
The first 94 patients put on risperidone were followed
up and assessed at baseline (week 0), week 1, week
4, week 24, and week 52. They were assessed by the
same doctors using the Clinical Global Impression
(CGI) and Global Evaluation (GE) scales. Data
collected also included thenumberofadmissions one
year prior to and one year after starting risperidone,
diagnosis, initial clinical status, as well as side effects.
The side effects noted were based on subjective and
objective observations. For patients who
discontinued UnNatmentwith risperidone, the reasons
for stopping were noted and data concerning the
previous medication, titration schedule and dosages
were collected. Data was collected using the
Risperidone Study Questionnaire. Changes in side
effects encountered while on the previous
antipsychotics were also noted.
Statistical Analysis
Measured values are expressed as means +/-SD
(standard deviation). Characteristics and clinical
ratings were compared using Wilcoxon's signed rank
test. All statistical tests were interpreted at the 5%
significance level (two-tailed).
Additional statistical analysis included summaries of
demographics and baseline data. Demographic
variables (age, sex, race, initial clinical status) were
summarized using frequency tables.
Results
In total 94 patients entered the study and data from
62 patients were used for statistical analysis as 32
patients discontinued. Reasons for treatment
discontinuation will be discussed in thenextsection.
Demographics
Of the 62 evaluated patients, 34 were Chinese
(54.8%), 16 were Malays (25.8%), and 12 were
Indians (19.4%). Thirty-three patients (53.2%)were
female and 29 patients (46.8%) were male.
The initial clinical status were treatment refractory
(42%), chronic controlled (42%), acute exacerbation
(21%), EPS prone (15%),1 •
 episode (2%), elective
switch-over (8%) and with combination of reasons
(1.5%). Out of the 62 patients with schizophrenia, 42
patients (67.7%) were treatment refractory. Eleven
patients of the treatment refractory group
discontinued the trial while 31 patients (73.8%)
completed the one-year treatment. The patients
mean age was 33.7 ± 11.9 yrs. (range 14 to 72).
Risperidone mean final dosage was 4.3 + 1.8 mg
(mode = 4 mg).
Efficacy Analysis
Primary Parameters
Mean CGI score decreased from 4.9 ± 1.0 at week 0
(baseline) to 2.5 t 0.8 at week 52 (endpoint), p <
0.001. This was an overallreduction of49.0%. There
was a significant reduction in the CGI scores when
comparing the scores at week 0 with those at week
1, 4, 26 and 52, p <0.001. A comparison ofthe mean
CGI scores indicated that the maximum reduction in
CGI scores occurred within the first 26 weeks. The
mean Global Evaluation by Investigator (GET) score
increased from 5.7 ± 0.9 at week 4 (baseline) to 6.5
t 0.9 at week 52 (endpoint), p < 0.001. This was an
overall improvement of 14.0%. Mean Global
Evaluation by Patient (GEP) score increased from
5.7±0.9 atweek4to 6.5* 1.0 atweek52 (endpoint),
p < 0.001. This was an overall improvement of
14.0%.
Table 1 • CGI.and GE whose mean (:SD) clinical rating were
reducedlmproved significantly
Item Baseline Endpoint
CGI 4.9±1.0 2.5±0.8
GEI 57±09 65±09***
GEP 5.7±0.9 6.5t1.0
CGI = Clinical Global Impression
GEI = Global Evaluation by Investigator
GEP - Global Evaluation by Patient
•" =p<0.001
Secondary Parameters
There was a 34.0% (n=32) discontinuation rate of
risperidone treatment with 37.5% (n = 12) reported
as having poor response, 3.1% (n = 1) having
galactorrhea or amenorhea, 6.3% (n = 2) having
headache, 3.1%(n = 1) died of asthma, 3.1%(n=1)
having diarrhea, 3.1%(n = 1) having blurred vision,
3.1% (n = 1) having palpitations, 9.4% (n = 3)
defaulted on follow-up, 15.6% (n = 5) due to cost
factor, 15.7% (n = 5) having persistent EPS. Nine
patients (28.1%) discontinued within the first month.
37
STEPHEN T. JAMBUNATHAN <+ at
Of the 12 patients (37.5%) reported as poor
responders, 10 patients (83.3%) were classified as
having treatment refractory schizophrenia. Among
these 10 patients who were treatment refractory, 4
patients were on risperidone 2mg b.d. for a period
ranging from one to six months, 2 patients were on
risperidone 3mg b.d. for a period of one to three
months, 2 patients were on risperidone 4mg b.d. for
a period of six months and 2 patients were on
risperidone4mg b.d. and haloperidol 30mg/day.
There was a 76.9% reduction in the number of
admissions one year post-treatment (endpoint) as
compared to week 0 (baseline), p < 0.001.
Of the 94 patients put on risperidone, 11 patients
(11.7%) discontinued the treatment because of side
effects. Side effects reported but did not lead to
discontinuation were weight gain (10 kg) (n=
 1),
tremors (n = 1), salivation (n =
 1), transient allopecia
(n = 1) and transient amenorrhoea (n =
 2).
7 patients were put on risperidone due to the
presence of tardive dyskinesia with 6 having a
reduction in symptoms and one patient having no
change. 5 patients were put on risperidone due to
prolactin-related side effects caused by the previous
neuroleptic with I patient completely recovering
while 3 patients showed partial. improvement.
Discussion
From this study, it was seen that risperidone was
significantly effective in the treatment of
schizophrenia. Based on the CGI and GE scores,
67.5% ofthepatients with schizophrenia and 73.8%
of the patients diagnosed as treatment refractory
schizophrenia responded to the treatment.
As mentioned earlier, there was a 73.8%
responder rate in treatment refractory schizophrenia
in terms ofpatient and doctor satisfaction . In a study
o f 74 patients by Addington et. al., there was a 63.5%
drop-out rate over a one-year period (16). In this
study, the drop out rate among treatment refractory
patients was 26.2%. The significantly lower rate
found here may be due to varying criteria used to
define treatment refractory. The criteria for treatment
refractory in this study was taken from the Food and
Drug Administration (FDA) guidelines for the
treatment of treatment-resistant schizophrenia.
Treatment resistance is defined as the failure to
respond to two adequate antipsychotics in trials
over a minimum period offour to six weeks each with
a dosage equivalent to 400mg per day of
chlorpromazine, adequate for blocking 80% to 90%
ofdopamine receptors (14). Similarly in other studies,
risperidone was found to be significantly effective in
treating refractory patients (10,15,16).
Compliance with antipsychotic medication is
another important factor in the maintenance of the
well being ofpatients. Factors influencing compliance
are persistent psychosis, poor insight by patient and
care givers, intolerable side effects and cognitive
dysfunction (4). Risperidone increases patient
compliance not only by reducing the severity of
psychosis butalso because ofits low incidence oflow
side effects (3,16,17). Out of the 94 patients put on
risperidone, 11 patients (11.7%) discontinued the
treatment due to side effects. In relation to this low
side effect profile, 7 patients were switched to
risperidone due to the presence oftardive dyskinesia
(TD). 6 of the patients showed a reduction in TD
within six months of using risperidone. One patient
reported no change in the severity of TD. Of the 6
patients who demonstrated improvement in TD, 2
patients had complete cessation of the oro-buccal
movement. Similar findings of improvement of TD
have been reported in other studies (4,5,6).
Therewas a 34.0% discontinuation ofrisperidone
treatment in this study. The duration of concomitant
medications (antipsychotics and anticholinergics),
duration of study with risperidone before
discontinuation, and duration of the switch-over
period were examined.
6 patients who showed poor response possibly
might have had symptoms of breakthrough or rebound
psychosis as the previous antipsychotic was
withdrawn by the first week. Anotherpossible cause
for the failure of treatment is the occurrence of
' cholinergic rebound'. This occurs when a low potency
antipsychotic or an anticholinergic medication is
withdrawn abruptly. This phenomenon is
characterized by changes in mental status such as
worsening psychosis, restlessness, agitation and
insomnia. Patients may also complain of altered
bowel motility, sialorrhea and excessive perspiration
(5,18,19). Apart from the possibility of true poor
response, because ofthe short switching-over period,
the possibility of rebound psychosis, cholinergic
rebound or agitation due to residual or reemergence
of EPS should be considered (20). In these cases, a
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longer switch-over period might have been more
appropriate in order to prevent these avoidable
causes ofthe discontinuation. A longer continuation
of the anticholinezgics may also help in controlling
the residual EPS and help patients cope with the
transient side effects of the newer medication. One
study involving 1,283 patients on risperidone showed
that there wag a lower rate of discontinuation when
patients were put on risperidone more gradually with
dose increments of risperidone between 0.5 —2 mg
per day. In that study there was a higher rate of
discontinuation when patients were put on dose
increments of 2 — 4mg per day. The study also
showed that patients put through a longer period of
"switching-over' had a better outcome (30). In this
study, as mentioned earlier, 10 out of 32 patients
who discontinued treatment (31.3%) geased all other
medications by the first week suggesting that the
switch-over period was too brief.
In this study, one patient developed galactoahoea
and amenorrhoea. Galactorrhoea and amenorrhoea
can occur as a result of raised prolactin secondary to
dopamine antagonism. Dopamine is the prolactin
inhibiting factor (PIF) that controls the release of
prolactin from the anterior pituitary. Other stpdies
have shown the incidence of prolactin related side
effects with risperidone to be between 0.8% to 9%
•(21,22,23). Another side effect reported was
palpitations. One patient developed this symptom
when on 4mg daily after a period of one month. The
incidence of palpitations was 14.4% and 22.7%
(23,24) in two separate studies. In comparison, the
incidence of palpitations was relatively low in this
study (1%).
• Studies have shown that the average dosage of
risperidone used was between 4 — 8mg per day with
one study suggesting the optimal dose to be 6mg per
day(12,17,26,27). In this study, themean final dose
was 4.3 mg per day with the mode being 4mg per day.
In treatment-resistant schizophrenia where patients
require high doses of antipsychotics of at least two
different groups, the study of risperidone of only
4mg per day could be considered inadequate. In view
of treatment resistance, risperidone could have been
used at a higher dosage and fora longer period of time
before being discontinued (12,26). One study showed
that patients continued to show improvement even
after 32 weeks (24). Based on the CGI and GE scores
as seen in this study, it is evident that our patients
continued to show significant improvement up to 6
months, indicating that in addition to having a short
onset of efficacy, risperidone continues to improve
symptoms on a more gradual basis.
During this study, two patients were put on 6mg
of risperidone daily for a period of one and three
months respectively. They were on a previous dosage
of chlorpromazine 600mg and 1700mg daily
respectively.. Although there is no suggested
equivalent dose ofrisperidone as compared to older
antipsychotics, nor a minimum period of study
beforepoorresponse can be claimed, ahigherdosage
of risperidone is indicated when there is a lack of
adequate response to a lower dose. Previous needs
for higher doses ofneuroleptics too could indicate the
need for higher doses ofrisperidone. A longer treatment
period would have been optimum for these patients
to benefit optimally from risperidone therapy.
A total of five patients discontinued treatment
because of persisting EPS. Three did not administer
any anticholinergics after stopping the previous
antipsychotic, while one patient who wasneuroleptic
naive took risperidone 4mg daily without any
anticholinergic medication. In the above-mentioned
four patients; adequate steps had not been taken to
prevent the re-emergence ofEPS or prevent the initial
transient intolerance ofrisperidone. The fifth patient
could not tolerate risperidone despite adequate
anticholinergics for approximately 2 months. Two
studies have shown that approximately 4.8% to 20%
of patients require anticholinergics concomitant to
risperidone treatment (12,21).
Switching patients from one antipsychotic to
another is sometimes necessary because ofinadequate
or incomplete therapeutic response or intolerable
side effects. Special precautions are necessary when
switching antipsychotics especially from a low
potency antipsychotic to a newer or atypical type.
This is because of the possibility of a 'cholinergic
rebound' which may mimic psychosis in its clinical
presentation or lead to a relapse due to the resulting
poor compliance (18,20). Neuroleptic intolerance as
such could be possibly due to true intolerance or lack
ofadequate anticholinergics medication.Inthis study,
three out offive patients who complained ofpersisting
EPS, and six out of twelve who had poor response,
discontinued risperidone prematurely due to the
persisting side effects and inadequate dosing that
could have been prevented respectively. With the
advent of atypical antipsychotics, the increasing
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'number of patients undergoing the process of
switching over to these newer medications will also
be subjected to a higher risk ofrelapses ifthe switch-
over is not done properly with appropriate
precautions being observed.
Psychoeducation is another important issue that
needs to be emphasized before the switch-over is
made. The patient and his or her family should be
made aware of the day to day consequences of
symptom change and their effects on relationships,
jobs and ability to function. The family and physician
should be prepared to spend more time with the
patient. More rehabilitative services are needed in
keeping with expectations of increased recovery
with the increased use of atypical antipsychotics.
These changes although very much desired and
expected could paradoxically become a stressor ifnot
managed, eventually causing a relapse. Changes in
symptoms and side effects should be explained
carefully. Symptoms may flare up during the period
of switching over as a result ofthe withdrawal ofthe
previousneuroleptic. Transient increase in side effects
too may occur especially during the initial phase. The
patient and family should be educated on these
possibilities before embarking on a treatment. It is
important to explain to the family that improvement
may be slow and that the degree ofimprovement may
be limited as the response to a new drug is never fully
predictable.
In this local setting, another important factor is
the presence of differing "prescribing philosophy".
Patients in the Kuala Lumpur and Selangor region
have access to three different psychiatric institutes:
the Kuala Lumpur Hospital, University of Malaya
Medical Centre and the Ulu Kinta Hospital. Often,
patients are admitted in one hospital with a subsequent
follow.-up in another hosp ital. Very often, the reasons
for a change in medication are not known by the
subsequent following up doctor. Medications deemed
as ineffective by one doctor may not have been in
keeping with the practice of the other doctor.
Unfortunately, the lack of continuity of treatment
for the more difficult patients or those requiring
longerperiodofhospitalization can leadto inadequate
evaluation ofany one medication. Considering other
compounding factors such as inadequate dosing,
reemergence of side effects from the previous
medication and the premature discontinuation due to
transient side effects, it is therefore necessary to
extend the period ofevaluation ofa drug while using
anticholinergics and perhaps anxiolytics at the same
time to deal with the side effects caused by the
previous medication.
Limitations of this study
This study was affected by the following limitations.
Firstly, the CGI and GEI assessments made by the
treating doctor are subjected to biases of the doctor.
Secondly, there was no matched control group to
compare the varying responses to risperidone.
Thirdly, changes in the positive and negative
symptoms were not evaluated. Lastly, this study
was not double blinded thus the results were subjected
to biases.
Conclusion
In this study the treating doctor and the patient were
both satisfied with the response seen with a
statistically significant reduction in the CGI and GE
scores by both parties and also a 76.9% reduction in
the number of hospitalizations (p<0.001).
Risperidone was also significantly effective in the
treatmentoftreatment refractory Schizophrenia with
a 73.8 % response rate.
The discontinuation oftreatment (34%) was due
to various factors such as side effects, poor response
and persistent EPS. There was a low incidence (11%)
of discontinuation due to side effects and a low
incidence ofEPS (5%). Some ofthese problems could
have been avoided had the patients been put on
adequate anticholinergics for the persistent EPS and
a higher dose ofRisperidone for a longer period for
the poor responders. Possible causes for the
discontinuation also include breakthrough psychosis
and cholinergic rebound often seen when switching
over of treatment is done over too short period.
Based on the results of this study, Risperidone
may have a role in the reduction o f tardive dyskinesia
in some patients. However more evidence has to be
found to support this finding. Over the one year on
Risperidone there were no reports of patients
developing tardive dyskinesia. The treatment with
risperidone was safe as no serious side effects
occurred.
Overall, based on these observations, the therapy
with risperidone was highly effective and safe. Finally,
considering the various influencing factors on the
response of a patient to treatment as seen in this
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study, it is important for us to have a more complete
approach when using a particular medicine or
switching a patient from one medication to another.
The factors to be considered here is described in a 6
D approach. The "Delivery" of the medication in
terms of compliance is the first factor to consider.
"Dose" and "Duration" of the drug used, the "Drug"
efficacy and eventually the "Diagnosis" are also
factors to be considered when response to treatment
is not satisfactory.. Finally, the "Distress" faced by
the patient in terms ofpsychosocial stressors should
be taken into consideration from the Very beginning
as that
.
 is something that can perpetuate an illness
often rendering a patient to be treatment refractory.
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